Thermo Fisher Scientific Inc (TMO)
Official siteHEALTHCARE • DIAGNOSTICS & RESEARCH • NYSE
Market Cap: $256.15B
Last updated: Nov 17, 2026 at 4:32 PM ET
Thermo Fisher Scientific Inc (TMO) Statistics
Thermo Fisher Scientific (TMO) has a market cap of $256.15B and an enterprise value of $292.06B. Its share count is down 2.12% from a year earlier.
Total Valuation
Enterprise value is 14.02% above the market cap, as debt exceeds cash.
| Market Cap | $256.15B |
|---|---|
| Enterprise Value | $292.06B |
| Latest price (Nov 17, 2026) | $687.29 |
Key Dates
The next earnings report is expected on Jan 27, 2027, covering the quarter ending Dec 31, 2026. The next ex-dividend date is Dec 15, 2026.
| Next Earnings Date | Jan 27, 2027 (expected) |
|---|---|
| Last Earnings Date | Oct 21, 2026 |
| Next Ex-Dividend Date | Dec 15, 2026 |
| Next Payment Date | Jan 15, 2027 |
| Fiscal Year End | December |
Valuation Ratios
Sales and book value multiples are 5.4x and 4.6x. Its year-end P/E ranged from 17.1x to 26.6x from 2016 to 2025.
| P/E Ratio | 27.8x |
|---|---|
| Forward P/E | 26.9x |
| P/S Ratio | 5.4x |
| Forward P/S | 5.3x |
| P/B Ratio | 4.6x |
| P/FCF Ratio | 33.5x |
| P/OCF Ratio | 27.5x |
| PEG Ratio | 2.7 |
Enterprise Valuation
Counting debt and cash, the company is valued at 25.1x EBITDA and 38.2x free cash flow.
| EV / Earnings | 41.2x |
|---|---|
| EV / Sales | 6.2x |
| EV / EBITDA | 25.1x |
| EV / EBIT | 34.5x |
| EV / FCF | 38.2x |
Price Statistics
The stock is up 18.97% over 52 weeks and trades 2.00% above its 50-day average.
| Beta (1Y) | 0.69 |
|---|---|
| 52-Week Change | +18.97% |
| 1-Month Change | +1.16% |
| 3-Month Change | +12.10% |
| 6-Month Change | +53.74% |
| 5-Year Change | +10.10% |
| 10-Year Change | +374.05% |
| Total Return (1Y) | +19.29% |
| Total Return (3Y CAGR) | +14.05% |
| Total Return (5Y CAGR) | +1.75% |
| Return vs SPY (1Y) | +7.97% |
| Max Drawdown (1Y) | -31.50% |
| Max Drawdown (3Y) | -37.27% |
| Sharpe Ratio (1Y) | 0.60 |
| Correlation with SPY (1Y) | 0.32 |
| 50-Day Average | $673.82 |
| 200-Day Average | $555.98 |
| 52-Week Range | $434.50 to $727.56 |
| RSI (14 Days) | 49.1 |
| Average Volume (20 Days) | 2.11M |
The 5 and 10 year changes compare month-end closes, adjusted for splits, through Oct 2026.
Financial Position
Current assets cover 1.81x current liabilities, and total debt is 0.76x shareholder equity.
| Current Ratio | 1.81x |
|---|---|
| Quick Ratio | 1.41x |
| Debt / Equity | 0.76x |
| Debt / EBITDA | 3.58x |
| Debt / FCF | 5.45x |
| Interest Coverage | 5.45x |
Returns and Efficiency
Return on invested capital is 7.97% over the last 12 months, against a 5-year average of 8.86%.
| Return on Equity (ROE) | 12.96% |
|---|---|
| Return on Assets (ROA) | 6.21% |
| Return on Invested Capital (ROIC) | 7.97% |
| Return on Capital Employed (ROCE) | 8.45% |
| ROE (5Y Average) | 14.58% |
| ROA (5Y Average) | 6.78% |
| ROIC (5Y Average) | 8.86% |
| Asset Turnover | 0.44x |
| Inventory Turnover | 4.95x |
| Receivables Turnover | 4.96x |
| Cash Conversion Cycle | 106 days |
Taxes
Income tax took 9.39% of pretax income over the last 12 months.
| Income Tax (TTM) | $742.00M |
|---|---|
| Effective Tax Rate | 9.39% |
Scores
TMO has an Altman Z-Score of 4.13, in the safe zone above 2.99, and a Piotroski F-Score of 5 of 9, in the average band of 3 to 7.
Altman Z-ScoreDistress below 1.81Safe above 2.99
Piotroski F-ScoreWeak at 2 or lessStrong at 8 or more
| Altman Z-Score | 4.13 |
|---|---|
| Altman Z Zone | Safe |
| Piotroski F-Score | 5 of 9 |
| Piotroski Strength | Average |
Income Statement
Revenue of $47.35B over the last 12 months is up 8.27% from the 12 months before.
| Revenue | $47.35B |
|---|---|
| Revenue Growth (YoY) | +8.27% |
| Gross Profit | $19.45B |
| Operating Income | $8.47B |
| Pretax Income | $7.90B |
| Net Income | $7.09B |
| EBITDA | $11.56B |
| EBIT | $8.46B |
| Reported EPS (TTM) | $24.72 |
Trailing 12 months through Sep 30, 2026.
Balance Sheet
Shareholder equity funds 47.94% of the $114.23B in total assets.
| Cash and Equivalents | $5.46B |
|---|---|
| Total Debt | $41.37B |
| Net Debt | $35.91B |
| Net Debt Per Share | $97.05 |
| Working Capital | $11.45B |
| Shareholder Equity | $54.76B |
| Book Value Per Share | $148.01 |
| Tangible Book Value | -$17.58B |
| Total Assets | $114.23B |
| Total Liabilities | $59.34B |
Balance sheet as of Sep 30, 2026.
Cash Flow
After $1.73B of capital spending, operating cash flow left $7.60B of free cash flow.
| Operating Cash Flow | $9.32B |
|---|---|
| Capital Expenditures | $1.73B |
| Free Cash Flow | $7.60B |
| FCF Per Share | $20.54 |
| Depreciation and Amortization | $3.11B |
| Dividends Paid | $673.00M |
Trailing 12 months through Sep 30, 2026.
Margins
The operating margin is 17.88%, against a 5-year average of 18.95%.
| Gross Margin | 41.08% |
|---|---|
| Operating Margin | 17.88% |
| Pretax Margin | 16.68% |
| Net Margin | 14.98% |
| EBITDA Margin | 24.42% |
| EBIT Margin | 17.86% |
| FCF Margin | 16.04% |
| Gross Margin (5Y Average) | 42.89% |
| Operating Margin (5Y Average) | 18.95% |
| Net Margin (5Y Average) | 15.79% |
Growth
Revenue fell 0.27% a year over 3 years, and EPS 0.53% a year.
| Revenue Growth (3Y CAGR) | -0.27% |
|---|---|
| Revenue Growth (5Y CAGR) | +6.70% |
| EPS Growth (3Y CAGR) | -0.53% |
| EPS Growth (5Y CAGR) | +3.19% |
| FCF Growth (3Y CAGR) | -3.07% |
| FCF Growth (5Y CAGR) | -1.58% |
| Operating Income Growth (3Y CAGR) | -2.64% |
| Book Value Per Share Growth (2Y CAGR) | +8.45% |
Dividends and Yields
TMO pays out 7.30% of earnings as dividends.
| Dividend Per Share (Annual) | $1.88 |
|---|---|
| Dividend Yield | 0.27% |
| Payment Schedule | Quarterly |
| Dividend Growth (3Y CAGR) | +12.75% |
| Dividend Growth (5Y CAGR) | +14.34% |
| Payout Ratio | 7.30% |
| FCF Payout Ratio | 8.86% |
| Earnings Yield | 3.60% |
| FCF Yield | 2.99% |
| Buyback Yield | 1.59% |
| Shareholder Yield | 1.85% |
Peer Position
Against 11 similar companies, TMO has the 7th highest P/E.
P/E RatioPeer median 28.4x
P/S RatioPeer median 6.4x
ROICPeer median 8.31%
Revenue Growth (Trailing 4 Quarters, YoY)Peer median +6.71%
Dividend YieldPeer median 0.00%
| P/E Ratio | 27.8x vs 28.4x median |
|---|---|
| P/S Ratio | 5.4x vs 6.4x median |
| ROIC | 7.97% vs 8.31% median |
| Revenue Growth (Trailing 4 Quarters, YoY) | +8.27% vs +6.71% median |
| Dividend Yield | 0.27% vs 0.00% median |
Analyst Forecast
Consensus estimates put revenue growth at 6.50% and EPS growth at 10.22% a year over the next 2 fiscal years.
| Revenue Growth Forecast (2Y CAGR) | +6.50% |
|---|---|
| EPS Growth Forecast (2Y CAGR) | +10.22% |
Price Target
Analyst price targets are part of paid GNG plans. See plans
GNG Valuation
| GNG view | Fairly valued |
|---|
GNG fair value is part of GNG Pro. See plans
Frequently Asked Questions About TMO
What is TMO's market cap?
Thermo Fisher Scientific has a market cap of $256.15B. Its enterprise value, which adds debt and subtracts cash, is $292.06B.
What is TMO's P/E ratio?
Thermo Fisher Scientific has a trailing P/E ratio of 27.8x and a forward P/E of 26.9x.
How many shares of TMO are outstanding?
Thermo Fisher Scientific has 370.00M shares outstanding. The count is down 2.12% from a year earlier.
Does TMO pay a dividend?
Yes. Thermo Fisher Scientific pays $1.88 a share a year, a dividend yield of 0.27%.
How much debt does TMO have?
Thermo Fisher Scientific has $41.37B of total debt and $5.46B of cash and equivalents, a net debt position of $35.91B.
TMO pages: Overview, Dividends, Charting, Earnings, Forecast, Financials, Statistics, Valuation, Competitors, Government Contracts